Tumor-Specific MHC-II Activates CD4⁺ and CD8⁺ T Cells in Head and Neck Squamous Cell Carcinoma to Boost Immunotherapy Efficacy

Investigators integrated single-cell RNA-sequencing and T cell receptor-sequencing to comprehensively characterize the tumor immune microenvironment (TIME) of head and neck squamous cell carcinoma biopsies prior to a Phase II neoadjuvant immunotherapy clinical trial.